MX356486B - Análogos sustituidos de la (e)-n' -(1-feniletiliden)benzohidrazida como inhibidores de la histona desmetilasa. - Google Patents

Análogos sustituidos de la (e)-n' -(1-feniletiliden)benzohidrazida como inhibidores de la histona desmetilasa.

Info

Publication number
MX356486B
MX356486B MX2014001842A MX2014001842A MX356486B MX 356486 B MX356486 B MX 356486B MX 2014001842 A MX2014001842 A MX 2014001842A MX 2014001842 A MX2014001842 A MX 2014001842A MX 356486 B MX356486 B MX 356486B
Authority
MX
Mexico
Prior art keywords
phenylethylidene
substituted
compounds
histone demethylase
inhiitors
Prior art date
Application number
MX2014001842A
Other languages
English (en)
Other versions
MX2014001842A (es
Inventor
David J Bearss
Hariprasad Vankayalapati
Venkataswamy Sorna
Steve L Warner
Sunil Sharma
Bret Stephens
Original Assignee
Univ Utah Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Utah Res Found filed Critical Univ Utah Res Found
Publication of MX2014001842A publication Critical patent/MX2014001842A/es
Publication of MX356486B publication Critical patent/MX356486B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)

Abstract

En un aspecto, la invención se relaciona con análogos de (E)-N'-(1 -feniletiliden)benzohidrazida sustituidos, derivados de los mismos, y compuestos relacionados, que son útiles como inhibidores de la histona desmetilasa específica de la lisina, incluyendo LSD1; métodos sintéticos para hacer los compuestos; composiciones farmacéuticas que comprenden los compuestos; y métodos para utilizar los compuestos y composiciones para tratar trastornos asociados con la disfunción de la LSD1; este resumen se pretende como una herramienta de exploración para los propósitos de investigación en la técnica particular, y no pretende ser limitante de la presente invención.
MX2014001842A 2011-08-15 2012-08-15 Análogos sustituidos de la (e)-n' -(1-feniletiliden)benzohidrazida como inhibidores de la histona desmetilasa. MX356486B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161523801P 2011-08-15 2011-08-15
PCT/US2012/050948 WO2013025805A1 (en) 2011-08-15 2012-08-15 Substituted (e)-n'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhiitors

Publications (2)

Publication Number Publication Date
MX2014001842A MX2014001842A (es) 2014-07-24
MX356486B true MX356486B (es) 2018-05-30

Family

ID=47715455

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014001842A MX356486B (es) 2011-08-15 2012-08-15 Análogos sustituidos de la (e)-n' -(1-feniletiliden)benzohidrazida como inhibidores de la histona desmetilasa.

Country Status (25)

Country Link
US (2) US8987335B2 (es)
EP (1) EP2744330B1 (es)
JP (1) JP6122006B2 (es)
KR (1) KR101983537B1 (es)
CN (1) CN103929960B (es)
AU (1) AU2012296639B2 (es)
BR (1) BR112014003382B1 (es)
CA (1) CA2843609C (es)
CY (1) CY1123345T1 (es)
DK (1) DK2744330T3 (es)
EA (1) EA026389B1 (es)
ES (1) ES2821548T3 (es)
HK (1) HK1200052A1 (es)
HR (1) HRP20201433T1 (es)
HU (1) HUE050962T2 (es)
IL (1) IL230728A (es)
IN (1) IN2014CN00961A (es)
LT (1) LT2744330T (es)
MX (1) MX356486B (es)
PL (1) PL2744330T3 (es)
PT (1) PT2744330T (es)
SG (1) SG2014009609A (es)
SI (1) SI2744330T1 (es)
WO (1) WO2013025805A1 (es)
ZA (1) ZA201400881B (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9266838B2 (en) 2011-08-15 2016-02-23 University Of Utah Research Foundation Substituted (E)-N′-(1-phenylethylidene)benzohydrazide analogs as histone demethylase inhibitors
CA2885969C (en) 2012-10-02 2021-04-06 Epitherapeutics Aps Substitued pyridine derivatives and compositions thereof useful as inhibitors of histone demethylases
US9650339B2 (en) * 2013-02-27 2017-05-16 Gilead Sciences, Inc. Inhibitors of histone demethylases
US9738637B2 (en) * 2013-03-12 2017-08-22 Celgene Quantical Research, Inc. Histone demethylase inhibitors
SG10201710543PA (en) * 2013-06-19 2018-02-27 Univ Utah Res Found Substituted (e)-n'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhibitors
ES2901711T3 (es) 2014-02-13 2022-03-23 Incyte Corp Ciclopropilaminas como inhibidores de LSD1
ME03580B (me) 2014-02-13 2020-07-20 Incyte Corp Ciklopropilamini kao lsd1 inhibitori
EP3105219B9 (en) 2014-02-13 2018-10-03 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
WO2015153516A1 (en) * 2014-04-04 2015-10-08 University Of Florida Research Foundation Hdac inhibitor compounds and methods of treatment
WO2015188130A1 (en) * 2014-06-05 2015-12-10 The University Of Kansas Marmelin analogs and methods of use in cancer treatment
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
WO2016007731A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyridines and imidazopyrazines as lsd1 inhibitors
WO2016007727A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
US9695180B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
BR112017003442A2 (pt) 2014-08-27 2017-11-28 Gilead Sciences Inc compostos e métodos para inibir histona desmetilases
EP2993175A1 (en) 2014-09-05 2016-03-09 IEO - Istituto Europeo di Oncologia Srl Thienopyrroles as histone demethylase inhibitors
CN106146361A (zh) * 2015-03-16 2016-11-23 四川大学 茚-1-亚基磺酰基苯甲酰肼衍生物及其制备方法和用途
SG11201708047UA (en) 2015-04-03 2017-10-30 Incyte Corp Heterocyclic compounds as lsd1 inhibitors
AU2016275702A1 (en) 2015-06-12 2017-12-21 Oryzon Genomics, S.A. Biomarkers associated with LSD1 inhibitors and uses thereof
WO2017013061A1 (en) 2015-07-17 2017-01-26 Oryzon Genomics, S.A. Biomarkers associated with lsd1 inhibitors and uses thereof
MY189367A (en) 2015-08-12 2022-02-08 Incyte Corp Salts of an lsd1 inhibitor
CN109195593A (zh) 2016-03-15 2019-01-11 奥莱松基因组股份有限公司 用于治疗实体瘤的lsd1抑制剂的组合
WO2017158136A1 (en) 2016-03-16 2017-09-21 Oryzon Genomics, S.A. Methods to determine kdm1a target engagement and chemoprobes useful therefor
AR109452A1 (es) 2016-04-22 2018-12-12 Incyte Corp Formulación farmacéutica de un inhibidor de lsd1 y método de tratamiento
EP3246330A1 (en) 2016-05-18 2017-11-22 Istituto Europeo di Oncologia S.r.l. Imidazoles as histone demethylase inhibitors
US11427543B2 (en) 2016-07-19 2022-08-30 The General Hospital Corporation Compounds for targeting cancer stem cells
WO2018083189A1 (en) 2016-11-03 2018-05-11 Oryzon Genomics, S.A. Biomarkers for determining responsiveness to lsd1 inhibitors
EP3535414A1 (en) 2016-11-03 2019-09-11 Oryzon Genomics, S.A. Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agents
MA51507A (fr) 2016-12-09 2020-11-11 Constellation Pharmaceuticals Inc Marqueurs pour un traitement personnalisé du cancer avec des inhibiteurs de lsd1
CN106831489B (zh) * 2017-03-23 2018-04-17 郑州大学 苯环丙胺酰腙类化合物、制备方法及其应用
SG11202000077RA (en) 2017-08-03 2020-02-27 Oryzon Genomics Sa Methods of treating behavior alterations
US10980777B2 (en) 2017-08-18 2021-04-20 Istituto Europeo Di Oncologia S.R.L. Indole derivatives as histone demethylase inhibitors
WO2019068326A1 (en) 2017-10-05 2019-04-11 Université D'aix-Marseille INHIBITORS OF LSD1 FOR THE TREATMENT AND PREVENTION OF CARDIOMYOPATHIES
UA128288C2 (uk) 2018-03-08 2024-05-29 Інсайт Корпорейшн СПОЛУКИ АМІНОПІРАЗИНДІОЛУ ЯК ІНГІБІТОРИ PI3K-<font face="Symbol">g</font>
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
CN109793742A (zh) * 2019-03-04 2019-05-24 四川大学华西医院 一种药物化合物应用
CN109758442B (zh) * 2019-03-20 2021-08-17 武汉大学 二芳基酰肼类化合物在制备抗流感病毒药物中的应用
AU2020242302A1 (en) 2019-03-20 2021-09-16 Oryzon Genomics, S.A. Methods of treating borderline personality disorder
WO2020188089A1 (en) 2019-03-20 2020-09-24 Oryzon Genomics, S.A. Methods of treating attention deficit hyperactivity disorder using kdm1a inhibitors such as the compound vafidemstat
EP3994280A1 (en) 2019-07-05 2022-05-11 Oryzon Genomics, S.A. Biomarkers and methods for personalized treatment of small cell lung cancer using kdm1a inhibitors
US20220047528A1 (en) * 2020-07-24 2022-02-17 Salarius Pharmaceuticals Llc Methods of inhibiting lysine-specific demethylase 1 (lsd-1)
EP3964204A1 (en) 2020-09-08 2022-03-09 Université d'Aix-Marseille Lsd1 inhibitors for use in the treatment and prevention of fibrosis of tissues
MX2023011779A (es) 2021-04-08 2023-11-22 Oryzon Genomics Sa Combinaciones de inhibidores de lsd1 para el tratamiento de canceres mieloides.
WO2023217758A1 (en) 2022-05-09 2023-11-16 Oryzon Genomics, S.A. Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors
WO2023217784A1 (en) 2022-05-09 2023-11-16 Oryzon Genomics, S.A. Methods of treating nf1-mutant tumors using lsd1 inhibitors
WO2024110649A1 (en) 2022-11-24 2024-05-30 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors and menin inhibitors for treating cancer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040110963A1 (en) * 2001-01-22 2004-06-10 Kaspar Burri Novel hydrazones
JP2002302472A (ja) * 2001-01-31 2002-10-18 Meiji Seika Kaisha Ltd メイラード反応阻害剤
JPWO2005007151A1 (ja) 2003-07-16 2006-08-31 株式会社医薬分子設計研究所 皮膚色素沈着の治療剤
WO2006136008A1 (en) 2005-05-24 2006-12-28 University Health Network Salicylic acid hydrazones as inhibitors of the erk mapkinase pathway and for the treatment of cancer
TW200800145A (en) 2005-08-26 2008-01-01 Dekk Tec Inc Hydrazone agents to treat cutaneous lesions
CN101541348A (zh) 2005-11-03 2009-09-23 红点生物公司 腙衍生物及其用途
US8338464B2 (en) 2006-11-30 2012-12-25 Albert Einstein College Of Medicine Of Yeshiva University Small molecule inhibitors of BCL6
EP2107908A4 (en) 2007-02-02 2011-07-20 Redpoint Bio Corp USE OF A TRPM5 INHIBITOR TO REGULATE INSULIN AND GLP-1 SECRETION
BRPI0809498A2 (pt) * 2007-04-02 2014-09-23 Inst Oneworld Health Compostos inibidores de cftr e seus usos
WO2009027349A2 (en) * 2007-08-24 2009-03-05 Oryzon Genomics Sa Treatment and prevention of neurodegenerative diseases
AR070898A1 (es) * 2008-03-18 2010-05-12 Solvay Pharm Bv Derivados de arilsulfonil pirazolin carboxamidina como antagonistas de 5-ht6
JP2011526925A (ja) 2008-07-01 2011-10-20 ザカロン ファーマシューティカルズ，インク． ヘパラン硫酸阻害剤
EP2376440A2 (en) * 2009-01-14 2011-10-19 Dow AgroSciences LLC Fungicidal compositions including hydrazone derivatives and copper
CA2727890A1 (en) 2010-01-13 2011-07-13 Norbert Kartner Compounds, compositions and treatments for v-atpase related diseases

Also Published As

Publication number Publication date
CA2843609C (en) 2020-12-08
WO2013025805A1 (en) 2013-02-21
DK2744330T3 (da) 2020-09-07
EP2744330B1 (en) 2020-07-15
IL230728A (en) 2017-05-29
EP2744330A4 (en) 2015-03-25
BR112014003382B1 (pt) 2022-03-15
ES2821548T3 (es) 2021-04-26
IN2014CN00961A (es) 2015-04-10
KR101983537B1 (ko) 2019-05-29
HK1200052A1 (en) 2015-07-31
HUE050962T2 (hu) 2021-01-28
SI2744330T1 (sl) 2020-11-30
IL230728A0 (en) 2014-03-31
KR20140077887A (ko) 2014-06-24
MX2014001842A (es) 2014-07-24
EA201490453A1 (ru) 2014-09-30
HRP20201433T1 (hr) 2020-12-11
EP2744330A1 (en) 2014-06-25
US20150150864A1 (en) 2015-06-04
ZA201400881B (en) 2015-07-29
SG2014009609A (en) 2014-05-29
JP2014527531A (ja) 2014-10-16
AU2012296639A1 (en) 2014-03-06
US20140094445A1 (en) 2014-04-03
PT2744330T (pt) 2020-10-01
CA2843609A1 (en) 2013-02-21
US9555024B2 (en) 2017-01-31
BR112014003382A2 (pt) 2017-11-21
CN103929960B (zh) 2016-08-17
LT2744330T (lt) 2020-10-26
EA026389B1 (ru) 2017-04-28
JP6122006B2 (ja) 2017-04-26
PL2744330T3 (pl) 2020-12-14
US8987335B2 (en) 2015-03-24
CN103929960A (zh) 2014-07-16
CY1123345T1 (el) 2022-03-24
AU2012296639B2 (en) 2016-06-09
NZ621078A (en) 2015-10-30

Similar Documents

Publication Publication Date Title
MX356486B (es) Análogos sustituidos de la (e)-n&#39; -(1-feniletiliden)benzohidrazida como inhibidores de la histona desmetilasa.
WO2014194280A8 (en) Novel suicidal lsd1 inhibitors targeting sox2-expressing cancer cells
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
EA033497B1 (ru) 1-(тиофенил или фенил)сульфонил-(пирролидин)-2-карбоксамидные производные и их применение в качестве антагонистов trpa1
MX2015018032A (es) Análogos sustituidos de (e)-n&#39;-(1-feniletiliden)benzohidrazida como inhibidores de histona desmetilasa.
EA201490357A1 (ru) Индазолы
BR112013025387A2 (pt) análogos substituídos da n-fenilpirimidin-2-amina como inibidores da quinase axl
NI201500142A (es) Derivados de 3-acetilamino-1 (fenil-heteroaril-aminocarbonil o fenil-heteroaril-carbonilamino) benceno para el tratamiento de desordenes hiperproliferativos.
EA201492281A1 (ru) Соединения n-арилтриазола в качестве антагонистов рецепторов лизофосфатидной кислоты (lpar)
PH12014502586A1 (en) Novel ring-substituted n-pyridinyl amides as kinase inhibitors
MX359882B (es) Amidas como moduladores de canales de sodio.
GEP201706735B (en) Kinase inhibitors
EA201500182A1 (ru) 4-МЕТИЛ-2,3,5,9,9b-ПЕНТААЗАЦИКЛОПЕНТА[a]НАФТАЛИНЫ
EA201490596A1 (ru) Новые производные дигидрохинолин-2-она
WO2014055928A3 (en) Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors
WO2014055934A3 (en) Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors
ECSP14030538A (es) Inhibidores de dgat1 de éter cíclico de cabeza de puente
EA201490471A1 (ru) Пиридазиноновые соединения и их применение в качестве ингибиторов daao
PE20150224A1 (es) Inhibidores del nampt
MX350862B (es) Acidos de piperidinil naftilacetico.
PH12017500351A1 (en) N-(2-(cyclic amine)ethyl)benzamide derivatives as p2x7 inhibitors
WO2013006734A8 (en) Substituted 4-phenoxyphenol analogs as modulators of proliferating cell nuclear antigen activity
EA201391586A1 (ru) ИНГИБИТОРЫ 17α-ГИДРОКСИЛАЗЫ/C-ЛИАЗЫ
CR20120274A (es) Procedimiento de sístesis y forma cristalina del hidrocloruro de 4-{3[cis-hexahidrociclopenta[c]pirrol-2-(1h)-il]propoxi} benzamida así como las composiciones farmacéuticas que la contienen
IN2012DN01661A (es)

Legal Events

Date Code Title Description
FG Grant or registration